Data

This free-to-watch webinar, brought to you by Certara, reviews best practices for using technology to overcome challenges in order to accelerate discovery programs.  Drug discovery research requires understanding complex chemical, biological, logistical, and computational data from a variety of data sources. A key challenge for discovery scientists is efficiently accessing the most relevant data from internal and […]

Results from the large, randomised COAST Phase II trial showed oleclumab, an anti-CD73 monoclonal antibody, or monalizumab, an anti-NKG2A monoclonal antibody, in combination with Imfinzi (durvalumab) improved progression-free survival (PFS) and objective response rate (ORR) compared to Imfinzi alone in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation […]

Beckley Psytech has dosed the first patient in a world-first clinical trial exploring the effects of psilocybin for treating Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA).   The outcome of the Phase Ib study, with proof-of-concept efficacy data, is expected to be available in early 2022. The clinical trial is being conducted as part of Beckley Psytech’s ongoing collaboration […]

Pluto Biosciences has launched a cloud-based, collaborative life sciences platform that leverages technology developed at the Wyss Institute for Biologically Inspired Engineering at Harvard University. The Pluto platform simplifies secure, collaborative data sharing and bioinformatics analysis for academic, biotech, and pharmaceutical organisations.   The Pluto platform was built to be a comprehensive digital lab space for life […]

UCB, a biopharmaceutical company, has presented new interim data from BE BRIGHT, an open-label extension (OLE) trial of an interleukin (IL)-17A/F inhibitor ‘bimekizumab’ for plaque psoriasis (PsO), at the 2021 American Academy of Dermatology (AAD) Summer Meeting. While the data are still preliminary, they strongly support a potential approval for bimekizumab in PsO and will […]

Appili Therapeutics has entered into a $3.5 million convertible security funding agreement with Lind Global Fund. The company intends to use the funding to advance the broader Appili pipeline, including ATI-2307, a novel clinical stage antifungal expected to enter Phase II study in 2022. It will also support the operations of the company as it […]

DDW Editor Lu Rahman selects three Canadian start-ups worth watching: AbCellera Biologics, BlueRock Therapeutics and Deep Genomics. AbCellera Biologics AbCellera Biologics was founded in 2012 as a spin out from the University of British Colombia. The company searches, decodes, and analyses natural immune systems to find antibodies that can be developed into drugs to prevent […]

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel medicines that can prevent life threatening infections, has released data from its recent Phase IIb clinical trial. In March 2021, the company announced that this study had met its primary endpoint, demonstrating a reduction of 2.5 log (>99%) in nasal Staphylococcus aureus […]

Paradigm4 has launched Reveal: Multi-Omics, an app which allows researchers to undertake advanced, cross-study analyses and enable quick searches for genes and proteins across integrated public reference and proprietary datasets. It is built on top of Paradigm4’s SciDB analytics platform, designed for rapid data slicing that enables scientific data modelling, storage, and population-scale computation. The […]

Vaccine development company Valneva has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553, by the US Food and Drug Administration (FDA). Breakthrough Therapy Designation intends to facilitate and expedite development and review of new drugs for serious or life-threatening conditions where preliminary clinical data demonstrates that the drug may have substantial […]